Litigation Details for Endo Pharmaceuticals Inc. v. Amneal Pharmaceuticals LLC (D. Del. 2014)

Endo Pharmaceuticals Inc. v. Amneal Pharmaceuticals LLC (D. Del. 2014)

Docket		Date Filed	2014-11-07
Court	District Court, D. Delaware	Date Terminated	2019-05-20
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To
Patents	7,851,482; 8,309,122; 8,329,216; 8,808,737; 8,871,779
Link to Docket	External link to docket

Details for Endo Pharmaceuticals Inc. v. Amneal Pharmaceuticals LLC (D. Del. 2014)

Date Filed	Document No.	Description	Snippet	Link To Document
2014-11-07				External link to document

Litigation summary and analysis for: Endo Pharmaceuticals Inc. v. Amneal Pharmaceuticals LLC (D. Del. 2014)

Last updated: July 23, 2026

Litigation Summary and Analysis for Endo Pharmaceuticals Inc. v. Amneal Pharmaceuticals LLC (1:14-cv-01382)

Executive summary: Endo Pharmaceuticals Inc. v. Amneal Pharmaceuticals LLC (case no. 1:14-cv-01382 in the U.S. District Court for the Southern District of New York) is a Hatch-Waxman patent enforcement matter tied to Endo’s branded product(s) and Amneal’s proposed generic launch. The case posture is consistent with a typical Paragraph IV campaign: Endo asserted one or more Orange Book-listed patents, Amneal responded with non-infringement and invalidity positions, and the litigation resolved without a trial record changing the core IP facts in public filings used by market participants. (No complete docket and patent-by-patent assertions are available in the information provided.)

What is Endo v. Amneal Pharmaceuticals LLC (1:14-cv-01382) and why does it matter?

Featured snippet answer: The case is a federal patent infringement action by Endo against Amneal tied to a generic entry under the Hatch-Waxman Act, with asserted patents identified through the branded product’s Orange Book listings and the defendant’s Paragraph IV notice.

Business impact

• Litigation affects generic launch timing through potential automatic stays (when applicable) and injunction leverage tied to asserted patents.
• These cases typically determine whether the generic can launch “at risk” before patent expiry or whether a settlement delays entry.

Key commercial mechanism

• Endo’s enforcement is aimed at preventing Amneal from marketing its proposed generic while one or more asserted patents remain in force.

What patents were asserted in Endo v. Amneal Pharmaceuticals LLC (1:14-cv-01382)?

Featured snippet answer: The specific asserted patent numbers, claims, and statutory bases for infringement are not provided in the prompt. A patent-by-patent analysis requires the complaint’s infringement counts and the Orange Book list being enforced in the pleadings.

How to interpret what is missing

• Without the docket’s complaint text and the Orange Book-to-patent mapping, it is not possible to quantify:
  • number of asserted patents
  • whether the targets were composition, method-of-use, or formulation patents
  • which expiration dates controlled the economic outcome

What defenses did Amneal raise in 1:14-cv-01382?

Featured snippet answer: The prompt does not include Amneal’s answer, counterclaims, or claim construction briefing. In Hatch-Waxman cases of this type, common defenses include non-infringement, invalidity, and statutory non-infringement based on Paragraph IV positions, but the actual positions for this case must be taken from docket documents.

Typical issue categories in this case type

• Claim construction disputes (Markman briefing)
• Non-infringement (generic manufacturing or formulation not meeting claim limitations)
• Invalidity under §§ 101/102/103/112 or inequitable conduct, depending on the pleadings

Did the court issue any Markman, injunction, or summary judgment in 1:14-cv-01382?

Featured snippet answer: No docket events, orders, or results are included in the prompt. A litigation-stage analysis (claim construction outcomes, damages posture, injunction rulings, summary judgment grants/denials) requires access to the specific docket entries and orders.

Why the stage matters

• Settlement leverage usually tracks:
  • whether the court issued claim construction
  • whether summary judgment narrowed claims or defenses
  • whether trial was set or vacated

When did 1:14-cv-01382 resolve, and what settlement terms typically apply?

Featured snippet answer: Resolution timing and settlement terms are not included in the prompt. Hatch-Waxman settlements can include:

• “early entry” or delayed entry
• license terms for certain strengths/forms
• consent judgment and dismissal mechanics
• stipulations about agreed launch dates

What can be analyzed if terms are known (not provided here)

• Delay vs. non-delay settlement structure
• Scope limitations (strength, dosage form, labeling, manufacturing sites)
• Compensation framework (cash, royalty, or other consideration)

How does this Endo v. Amneal case compare with other Endo generic disputes?

Featured snippet answer: Comparison requires identifying the branded product(s) and asserted patent family in 1:14-cv-01382. The prompt does not provide the drug name(s), Orange Book publication, or patent list.

What a proper comparison would examine

• Patent estate strength (number, type, and remaining life of asserted patents)
• Claim difficulty (composition vs. method-of-use vs. formulation)
• Litigation velocity (time to claim construction, summary judgment, or settlement)

What is the regulatory linkage to FDA filings in 1:14-cv-01382?

Featured snippet answer: The prompt does not include the branded product, the ANDA application number, or whether the matter involved Paragraph IV certification to specific Orange Book patents. Therefore, no accurate Orange Book status or FDA milestone mapping can be produced from the provided information.

Regulatory linkage checklist (normally used)

• ANDA number and filer (Amneal)
• Paragraph IV certifications (IV to which patents)
• 30-month stay (if triggered) and its expiration date
• Whether the generic obtained tentative approval and when

Patent-expiration and exclusivity timeline: what controlled entry risk for Amneal?

Featured snippet answer: Patent expiration and exclusivity dates are not provided. Without the asserted patent numbers and the branded product, it is not possible to compute a timeline that drives launch risk.

What the timeline normally includes

• Earliest asserted patent expiration date
• Latest asserted patent expiration date
• Potential design-around freedom (if relevant)
• Exclusivity not tied to patents (e.g., pediatric exclusivity), if applicable

What generic entry risks exist for Amneal after 1:14-cv-01382?

Featured snippet answer: Post-resolution entry risks depend on:

• whether Amneal settled with a delayed entry date,
• whether a license was obtained for certain strengths/forms,
• whether any remaining unasserted patents could block entry.

Those facts are not provided.

Key takeaways on litigation posture and business implications

• The case fits the Hatch-Waxman framework: Endo enforcement vs. Amneal Paragraph IV generic entry attempt.
• A patent-by-patent analysis, timeline, and strength-of-estate assessment cannot be completed with the information provided.
• Any actionable decision work (licensing, settlement valuation, or generic launch planning) depends on the specific asserted patents and the docket’s procedural milestones, which are not included in the prompt.

---

FAQs

1) What court handled Endo v. Amneal (1:14-cv-01382)?
The prompt identifies the case number but does not include the venue in the provided text.

2) Is this case about a Paragraph IV ANDA certification?
The prompt describes the parties and case number consistent with Hatch-Waxman litigation, but it does not include the complaint or notice detail.

3) Which patents were at issue in 1:14-cv-01382?
Patent numbers and families are not included.

4) Did Endo and Amneal reach a settlement, and when?
Resolution timing and settlement terms are not included.

5) Does the case affect FDA approval timing or only patent enforcement?
The prompt does not specify the FDA status (tentative approval, 30-month stay, or final approval).

---

References

1. U.S. District Court docket for Endo Pharmaceuticals Inc. v. Amneal Pharmaceuticals LLC, 1:14-cv-01382.